Gossypol + Chemo for Advanced Colorectal Cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of gossypol acetate, FOLFIRI, and bevacizumab for people with metastatic colorectal cancer that has certain gene changes (TP53 and LRPPRC). It is for those who have already tried an oxaliplatin-based treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older with advanced colon or rectal cancer that has spread and cannot be removed by surgery.
- Your cancer must have changes in the TP53 gene and be positive for LRPPRC.
- You must have received only one prior treatment for your cancer that included oxaliplatin.
- You must be in generally good health, able to care for yourself (ECOG 0-2), and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two drugs – sintilimab (an immunotherapy that helps your immune system fight cancer) and gossypol acetate (a targeted therapy) – for people with advanced colorectal cancer that has not responded to at least two prior treatments and whose tumors have a specific genetic profile (pMMR/MSS).
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
This Phase 2 trial tests whether bevacizumab plus oxaliplatin and TAS-102 works better and is safe as the first treatment for advanced colorectal (colon/rectum) cancer. You may be asked to meet specific health and blood-test requirements and avoid other cancer treatments during the study.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
This trial tests a combination of three drugs (doxorubicin liposome, capecitabine, oxaliplatin, and bevacizumab) as a first treatment for advanced colorectal cancer that has a specific SMAD4 gene mutation. The goal is to see if this combination shrinks tumors and is safe for patients who have not had chemotherapy before.
This trial tests a new drug called SAR445877 combined with two standard chemotherapies (FOLFOX and bevacizumab) as an initial treatment for people whose colorectal cancer has spread and is microsatellite stable (MSS). It aims to see if adding this drug works better than standard therapy alone.
Hear when a new Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.